About SonoThera
SonoThera is a biotechnology company developing an ultrasound-mediated, nonviral genetic medicine platform (RIPPLE™) that uses microbubble-mediated sonoporation to deliver DNA, RNA, gene-editing tools, and other nucleic acid payloads to targeted tissues without viral vectors. Its technology enables redosable, size-unrestricted genetic payload delivery across multiple organs including muscle, kidney, liver, and heart. The company is advancing therapeutic candidates for diseases such as Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease.
Company details
Funding
Total raised
$60.8M
Last stage
Series A
Investors
Founders
Michael Davidson
Cardiologist and co-founder of SonoThera. Recognized the potential of microbubbles for gene delivery alongside Steve Feinstein.
Steve Feinstein
Cardiologist who invented the first two FDA-approved ultrasound contrast agents (microbubbles). Pioneer in applying microbubbles to gene therapy delivery.
Kenneth Greenberg
PhD in Visual Neuroscience from UC Berkeley. Has 20+ years of biotech experience in gene therapy and drug discovery. Previously co-founded Oncorus and CODA Biotherapeutics, and led external innovation at Janssen/J&J.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.